<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Medicine</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/72A324FF-B975-443D-BDD8-19E9649401E7"><gtr:id>72A324FF-B975-443D-BDD8-19E9649401E7</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:otherNames>Brian</gtr:otherNames><gtr:surname>Pepys</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5DABC140-76D1-49D2-BDB6-0366C03E390E"><gtr:id>5DABC140-76D1-49D2-BDB6-0366C03E390E</gtr:id><gtr:firstName>Aroon</gtr:firstName><gtr:otherNames>Dinesh</gtr:otherNames><gtr:surname>Hingorani</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5424B5E5-25D2-4542-94FD-959A58B8EE69"><gtr:id>5424B5E5-25D2-4542-94FD-959A58B8EE69</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:otherNames>Royston</gtr:otherNames><gtr:surname>Webster</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8AAA13A3-18F1-4CA1-943B-214C036C2080"><gtr:id>8AAA13A3-18F1-4CA1-943B-214C036C2080</gtr:id><gtr:firstName>Alun</gtr:firstName><gtr:otherNames>David</gtr:otherNames><gtr:surname>Hughes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/EC808D65-0A0E-494E-A129-C5C0FFCC548B"><gtr:id>EC808D65-0A0E-494E-A129-C5C0FFCC548B</gtr:id><gtr:firstName>Astrid</gtr:firstName><gtr:surname>Fletcher</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/073A7DAD-54FF-4F15-BC33-2DB0DFE42E83"><gtr:id>073A7DAD-54FF-4F15-BC33-2DB0DFE42E83</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:otherNames>A</gtr:otherNames><gtr:surname>Thom</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601354"><gtr:id>768E2EC2-DBEF-4EEE-BDD6-9C2D75F7B51C</gtr:id><gtr:title>Complement factor H: role in prediction and pathogenesis of age-related macular disease (AMD) and coronary heart disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601354</gtr:grantReference><gtr:abstractText>Inflammation refers to the natural response of the body to an infection. For example, localised pain, redness, swelling and warmth are are well-recognised features of an infected cut and are caused by the influx of circulating white blood cells and their release of chemical mediators that help to fight invading bacteria or viruses. Perhaps surprisingly, a state of grumbling, long-lasting, low-grade, generalised inflammation may exist in all of us as we get older, without us being aware of it. This low-grade inflammation may not be caused by bacteria or viruses but rather might be triggered by dead or dying cells, or certain by-products of our metabolism. This type of inflammation, that can be assessed by measuring the concentration of certain protein markers of inflammation in a blood test, has been implicated in the development of several common diseases of later life including heart disease, diabetes, Alzheimer s disease and age-related macular disease (AMD), a common form of blindness. Recent genetic studies show that some individuals who carry a common variant form of a gene that makes a protein called complement factor H (CFH) are at higher risk of AMD and heart disease. Since CFH is a protein that can help to damp-down one part of the inflammatory response it may be that the gene variant causes lower levels of CFH, but there is much to be learnt about how the altered gene leads to disease. For such studies, it is critical to be able to measure both the genetic variation and the level of CFH in the same indidvidual from large within a large populations with, or at risk of AMD or heart disease. We have developed a rapid high-throughput blood test for CFH, and we now aim to use it to measure CFH and the genetic variants in several large groups of individuals with, or at risk of, AMD and heart disease to understand if a deficiency of this protein underlies the risk of these two disorders. If so, measuring fH itself and/or its genetic variant may help to assess an individual s risk of AMD and/or heart disease, and medicines could be designed that modify the levels of CFH or the other factors it influences to reduce the risk of developing these two common and serious disorders of later life.</gtr:abstractText><gtr:technicalSummary>AMD is the commonest irreversible cause of elderly blindness in the developed world and coronary heart disease (CHD) the leading cause of death and morbidity. Inflammation is implicated in both disorders, but the link between inflammation and CHD, the more studied, is largely observational, and therefore susceptible to confounding. The naturally randomised allocation of genotypes at conception, balancing the distribution of potential confounding factors among genotypic classes, makes genetic associations less prone to biases that limit causal inference from observational studies. Consistently elevated AMD risk among carriers of common single nucleotide polymorphisms (SNPs) in the gene (OMIM: CFH Ch1q32) for complement factor H (CFH), a circulating inhibitor of complement activation, provides compelling evidence that CFH has a causal role in AMD. CFH SNPs are also linked to CHD risk, but there are fewer studies, and there are no large-scale studies of the relationship of fH level to genotypes or AMD or CHD risk. Therefore measurement of fH, or CFH genotyping, may help predict AMD or CHD risk, and fH may be a therapeutic target in these common disorders of ageing. We propose to: (1) link traditional observational studies of fH with genotyping for common polymorphisms in the CFH gene region to confirm the causal relevance of fH in AMD and investigate its potential role in the pathogenesis of CHD; (2) evaluate whether assay of fH itself, CFH genotype, or both, enhance the prediction of AMD or CHD; and (3) test associations of fH with established risk factors and novel biomarkers to evaluate the determinants of its variance in a population, and elucidate the scope for modification of its circulating concentration by available interventions.</gtr:technicalSummary><gtr:fund><gtr:end>2010-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1034615</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Epidemiology Unit</gtr:department><gtr:description>Genome wide association study for complement factor H in the MRC Fenland Study</gtr:description><gtr:id>836F7FE9-8D90-4911-8178-43E54146145F</gtr:id><gtr:impact>The data analysis is underway a high impact publication is expected.</gtr:impact><gtr:outcomeId>B44EE222E8F-1</gtr:outcomeId><gtr:partnerContribution>Allowed us to undertake a GWAS for fH based on existing Genome Wide SNP data in MRC Fenland</gtr:partnerContribution><gtr:piContribution>Measurement of fH using an assay developed s part of the biomarker award</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine</gtr:department><gtr:description>Collaboration on specificity of fH antibody with prof paul Morgan, Cardiff University</gtr:description><gtr:id>567689DC-687C-4E0C-87DA-EEF1E12B5262</gtr:id><gtr:impact>The data arising from this collaboration have been included in a forthcoming paper &amp;quot;Distribution and determinants of circulating complement factor H determined using a high-throughput immuno-nepholometric assay&amp;quot; in preparation for Clinical Chemistry</gtr:impact><gtr:outcomeId>Y8z7EPJ5XUA-1</gtr:outcomeId><gtr:partnerContribution>Prof Morgan's group conducted experiments to delineate the specificity of the fH anybody used in the assay developed as part of the MRC Biomarker Award</gtr:partnerContribution><gtr:piContribution>We provided the antibody and helped to interpret the experiments on specificity</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with Imperial Meningitis GWAS group</gtr:description><gtr:id>CEC963F3-9831-4503-AD45-D4B49991521F</gtr:id><gtr:impact>None to date</gtr:impact><gtr:outcomeId>kK9D9t7Q6ek-1</gtr:outcomeId><gtr:partnerContribution>They coordinate the international meningococcal GWAS studies</gtr:partnerContribution><gtr:piContribution>We are collaborating with this group on a joint paper comparing and contrasting the variants in the CFH gene region associated with AMD and meningitis together with their effect on fH level</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>900000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UCLH/UCL Biomedical Research Centre</gtr:department><gtr:description>UCL/ UCLH BRC</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>298528A0-31BC-4811-B013-E4FA0003F0F8</gtr:id><gtr:outcomeId>si7eyyPDwPk</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>We developed a high-throughput nephelometric assay for complement factor H based on existing reagents</gtr:description><gtr:id>0E772DE4-6D16-4F85-AB41-38ED32940878</gtr:id><gtr:impact>The development process is currently at the stage of evaluating the diagnostic/predictive utility of fH measurement in age-related macular degeneration</gtr:impact><gtr:outcomeId>WG8M7dReS5D</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>On hold</gtr:status><gtr:title>Nephelometric assay for complement factor H</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A consortium of studies of AMD with clinical and biological data including DNA</gtr:description><gtr:id>3FA82F0C-9CD4-44EC-B59D-7E89FAA10875</gtr:id><gtr:impact>A framework of studies has been put in place that has been the subject of a Wellcome Trust Start Grant for Clinical Lecturers; applicant Dr Sofat</gtr:impact><gtr:outcomeId>Pc3yhNuNVPq</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Consortium of Age related macular degeneration case control studies</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>An nephelometric assay</gtr:description><gtr:id>6300E2B0-5D97-4A91-AE56-706DF3D9CA4A</gtr:id><gtr:impact>None to date because we are currently analysing data and preparing publications</gtr:impact><gtr:outcomeId>2D1FD6726B8</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>A high throughput assay method for factor H applicable on a population scale</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B8EE1BB6-7BB6-49B5-8B30-7B4ED76F697E</gtr:id><gtr:title>Circulating Apolipoprotein E Concentration and Cardiovascular Disease Risk: Meta-analysis of Results from Three Studies.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4cf513374aefc525998bd45102347c56"><gtr:id>4cf513374aefc525998bd45102347c56</gtr:id><gtr:otherNames>Sofat R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>58c95fad4b5f08.22260299</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE4949D9-FB61-4A87-947D-E32480DDB25E</gtr:id><gtr:title>Distribution and determinants of circulating complement factor H concentration determined by a high-throughput immunonephelometric assay.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4cf513374aefc525998bd45102347c56"><gtr:id>4cf513374aefc525998bd45102347c56</gtr:id><gtr:otherNames>Sofat R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn><gtr:outcomeId>pm_13505_25_23376722</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16AE5042-319B-4DDE-93E7-1B814895A875</gtr:id><gtr:title>Evidence of association of APOE with age-related macular degeneration: a pooled analysis of 15 studies.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1578f0255e4dea71ffc3de53a6f650d2"><gtr:id>1578f0255e4dea71ffc3de53a6f650d2</gtr:id><gtr:otherNames>McKay GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>pm_16576_26_21882290</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23310127-EFF4-44FE-BC05-E21828780601</gtr:id><gtr:title>Genetic variation in complement factor H and risk of coronary heart disease: eight new studies and a meta-analysis of around 48,000 individuals.</gtr:title><gtr:parentPublicationTitle>Atherosclerosis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4cf513374aefc525998bd45102347c56"><gtr:id>4cf513374aefc525998bd45102347c56</gtr:id><gtr:otherNames>Sofat R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9150</gtr:issn><gtr:outcomeId>scCjtFEuqDT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>631D7CD3-060F-45D8-88FD-1F15630AB57B</gtr:id><gtr:title>Genetic variants associated with Von Willebrand factor levels in healthy men and women identified using the HumanCVD BeadChip.</gtr:title><gtr:parentPublicationTitle>Annals of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f77d593c25ed325f895f23e538023a02"><gtr:id>f77d593c25ed325f895f23e538023a02</gtr:id><gtr:otherNames>Zabaneh D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-4800</gtr:issn><gtr:outcomeId>pm_16576_26_21534939</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3BA744CC-853E-4BC2-8B24-7737BFA0ED28</gtr:id><gtr:title>An ecological correlation study of late age-related macular degeneration and the complement factor H Y402H polymorphism.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/deb14a5a94b177070b11763c269583c3"><gtr:id>deb14a5a94b177070b11763c269583c3</gtr:id><gtr:otherNames>Nonyane BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn><gtr:outcomeId>fgC49DcgaYo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DFA1CA18-CFC3-4B06-8F11-2E776ADF91AE</gtr:id><gtr:title>Variations in apolipoprotein E frequency with age in a pooled analysis of a large group of older people.</gtr:title><gtr:parentPublicationTitle>American journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1578f0255e4dea71ffc3de53a6f650d2"><gtr:id>1578f0255e4dea71ffc3de53a6f650d2</gtr:id><gtr:otherNames>McKay GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0002-9262</gtr:issn><gtr:outcomeId>pm_16576_26_21498624</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42730832-FB30-46B3-AE45-372D8ED85812</gtr:id><gtr:title>ARMS2 increases the risk of early and late age-related macular degeneration in the European Eye Study.</gtr:title><gtr:parentPublicationTitle>Ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b244f6a4a694ac02062b105337fdf7a"><gtr:id>4b244f6a4a694ac02062b105337fdf7a</gtr:id><gtr:otherNames>Chakravarthy U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0161-6420</gtr:issn><gtr:outcomeId>pm_16576_26_23098369</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6C173AA-131D-48A2-80CC-66D00EC1B730</gtr:id><gtr:title>Complement factor H genetic variant and age-related macular degeneration: effect size, modifiers and relationship to disease subtype.</gtr:title><gtr:parentPublicationTitle>International journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4cf513374aefc525998bd45102347c56"><gtr:id>4cf513374aefc525998bd45102347c56</gtr:id><gtr:otherNames>Sofat R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0300-5771</gtr:issn><gtr:outcomeId>jpQPExdhsHh</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601354</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>7EE9741E-CF94-420A-B0AB-A7811523CF2C</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Skin</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>